NCT06253117View on ClinicalTrials.gov

Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2028

Conditions
Recurrent Acute Pancreatitis
Interventions
DRUG

Pirfenidone

"Pirfenidone Days 1-7: 267 mg PO TID (801 mg/day) Days 8-14: 534 mg PO TID (1602 mg/day) Day 15 and thereafter: 801 mg PO TID; not to exceed 2403 mg/day~Duration of treatment- total 6 months"

DRUG

Placebo

Placebo

Trial Locations (2)

35294

RECRUITING

UAB, Birmingham

55905

RECRUITING

Mayo Clinic, Rochester

All Listed Sponsors
collaborator

Congressionally Directed Medical Research Programs

FED

lead

University of Alabama at Birmingham

OTHER